586 related articles for article (PubMed ID: 32885754)
1. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterial tuberculosis Enzyme Targets and their Inhibitors.
Saxena AK; Singh A
Curr Top Med Chem; 2019; 19(5):337-355. PubMed ID: 30806318
[TBL] [Abstract][Full Text] [Related]
3. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis.
Kinnings SL; Liu N; Buchmeier N; Tonge PJ; Xie L; Bourne PE
PLoS Comput Biol; 2009 Jul; 5(7):e1000423. PubMed ID: 19578428
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
Armstrong T; Lamont M; Lanne A; Alderwick LJ; Thomas NR
Bioorg Med Chem; 2020 Nov; 28(22):115744. PubMed ID: 33007556
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
Inturi B; Pujar GV; Purohit MN
Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
[TBL] [Abstract][Full Text] [Related]
6. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
7. Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis.
Matviiuk T; Madacki J; Mori G; Orena BS; Menendez C; Kysil A; André-Barrès C; Rodriguez F; Korduláková J; Mallet-Ladeira S; Voitenko Z; Pasca MR; Lherbet C; Baltas M
Eur J Med Chem; 2016 Nov; 123():462-475. PubMed ID: 27490025
[TBL] [Abstract][Full Text] [Related]
8. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
[TBL] [Abstract][Full Text] [Related]
9. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
[TBL] [Abstract][Full Text] [Related]
11. Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
Stec J; Onajole OK; Lun S; Guo H; Merenbloom B; Vistoli G; Bishai WR; Kozikowski AP
J Med Chem; 2016 Jul; 59(13):6232-47. PubMed ID: 27275668
[TBL] [Abstract][Full Text] [Related]
12. A piperidinol-containing molecule is active against
Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
[No Abstract] [Full Text] [Related]
13. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
14. Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis.
Divita KM; Khatik GL
Curr Top Med Chem; 2021; 21(18):1623-1643. PubMed ID: 34517802
[TBL] [Abstract][Full Text] [Related]
15. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
16. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
Salifu EY; Agoni C; Olotu FA; Soliman MES
Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
[TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
18. Exploring disordered loops in DprE1 provides a functional site to combat drug-resistance in Mycobacterium strains.
Liu J; Dai H; Wang B; Liu H; Tian Z; Zhang Y
Eur J Med Chem; 2022 Jan; 227():113932. PubMed ID: 34700267
[TBL] [Abstract][Full Text] [Related]
19. The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the
Ezquerra-Aznárez JM; Degiacomi G; Gašparovič H; Stelitano G; Sammartino JC; Korduláková J; Governa P; Manetti F; Pasca MR; Chiarelli LR; Ramón-García S
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054958
[TBL] [Abstract][Full Text] [Related]
20. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
Venugopala KN; Deb PK; Pillay M; Chopra D; Chandrashekharappa S; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Kandeel M; Venugopala R; Mohanlall V
Curr Top Med Chem; 2021; 21(4):295-306. PubMed ID: 33138763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
